European CHMP recommends Phesgo (pertuzumab / trastuzumab) for treatment of early and metastatic breast cancer

Phesgo is administered as a subcutaneous, fixed-dose combination offering patients a less invasive and faster administration as a single product, compared to the current administration of intravenous pertuzumab and subcutaneous trastuzumab formulations.

Source:

European Medicines Agency